You're describing a molecule with a rather specific chemical structure and potential applications. Let's break down the name and explore its potential importance.
**1-(Diiodomethyl)sulfonyl-4-methyl benzene**
* **1-(Diiodomethyl)sulfonyl:** This part indicates a sulfonyl group (-SO2-) attached to a carbon atom that is also attached to two iodine atoms (-CH(I)2).
* **4-methyl benzene:** This refers to a benzene ring (a six-membered carbon ring with alternating double bonds) with a methyl group (-CH3) attached at the fourth carbon position.
**Putting it Together:**
The full name tells us we have a benzene ring with a methyl group and a sulfonyl group attached to it. The sulfonyl group is further linked to a carbon atom that carries two iodine atoms.
**Importance in Research**
The presence of iodine atoms and the sulfonyl group makes this molecule potentially interesting for various research areas, including:
* **Medicinal Chemistry:** Iodine-containing compounds often exhibit biological activity and are used in drug discovery. The sulfonyl group can also contribute to drug-like properties.
* **Materials Science:** The sulfonyl group can be used to create functionalized materials for applications such as polymers, coatings, and catalysts. The iodine atoms could provide unique properties like enhanced reactivity or improved surface interactions.
* **Organic Synthesis:** The molecule itself may serve as a starting material or reagent for synthesizing other complex organic compounds. The iodine atoms and the sulfonyl group can be manipulated in various reactions.
**Specific Applications:**
Without further context, it's difficult to pinpoint the precise research applications of this molecule. To understand its full significance, one would need more information:
* **What specific research field is being investigated?**
* **What are the intended properties or functionalities of this molecule within that field?**
**To summarize:** 1-(Diiodomethyl)sulfonyl-4-methyl benzene is a potentially useful molecule in research due to the presence of iodine atoms and the sulfonyl group. Its specific importance hinges on the context of the research area and intended application.
1-(diiodomethyl)sulfonyl-4-methyl benzene: RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 62738 |
CHEMBL ID | 1884140 |
SCHEMBL ID | 21818 |
MeSH ID | M0205252 |
Synonym |
---|
benzene, 1-[(diiodomethyl)sulfonyl]-4-methyl- |
diiodomethyl p-tolyl sulfone |
einecs 243-468-3 |
benzene, 1-((diiodomethyl)sulfonyl)-4-methyl- |
p-((diiodomethyl)sulphonyl)toluene |
amical 48 |
1-(diiodomethyl)sulfonyl-4-methyl benzene |
1-((diiodomethyl)sulfonyl)-4-methylbenzene |
epa pesticide chemical code 101002 |
brn 2212639 |
caswell no. 353b |
NCGC00163712-01 |
1-(diiodomethylsulfonyl)-4-methylbenzene |
FT-0650296 |
A814171 |
iodo-methylsulfonyl-(p-tolyl)-$l^{3}-iodane |
20018-09-1 |
fdj36qmi3h , |
unii-fdj36qmi3h |
hsdb 8033 |
AKOS015890443 |
4-(diiodomethylsulfonyl)toluene |
diiodomethyl 4-methylphenyl sulfone |
diiodomethyltolylsulfone [inci] |
4-(diiodomethylsulfonyl) toluene |
diiodomethyltolylsulfone |
diiodomethyl 4-tolyl sulfone |
diiodomethyl p-tolyl sulphone |
4-tolyl diiodomethyl sulfone |
sulfone, diiodomethyl p-tolyl |
SCHEMBL21818 |
diiodomethyl-p-tolylsulphone |
cas-20018-09-1 |
NCGC00356977-01 |
dtxcid1012541 |
dtxsid3032541 , |
tox21_303744 |
CHEMBL1884140 |
c8h8i2o2s |
p-[(diiodomethyl)sulphonyl]toluene |
mfcd00072720 |
66456-97-1 |
tolyl diiodomethyl sulfone |
DS-5005 |
Q11310933 |
1-[(diiodomethyl)sulfonyl]-4-methylbenzene |
CS-W019145 |
Excerpt | Reference | Relevance |
---|---|---|
" These data were compared to iodide toxicokinetic results of a reproductive toxicity study for DIMPTS (80 mg/kg/day) and MPTS (32 mg/kg/day), where DIMPTS was toxic to dams and pups, while MPTS caused no toxicity." | ( Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. Brzak, KA; Clark, AJ; Saghir, SA; Staley, JL; Yano, BL; Zablotny, CL, 2012) | 0.38 |
" This MOA evaluation also addresses the potential for toxicity and adverse health outcomes during critical windows of development for different tissues." | ( Diiodomethyl-p-tolylsulfone: evaluation of the mode of action for reproductive toxicity. Poole, A; Saghir, SA, 2012) | 0.38 |
" The toxicological effects noted in the two mammalian species are consistent with the principal toxic effects of iodine, and are proposed to arise from release of iodide from the DIMPTS molecule with toxic sequelae." | ( Subchronic toxicity and genotoxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in laboratory animals. Berdasco, NA; Pitt, JA; Saghir, SA; Spencer, PJ, 2012) | 0.38 |
Excerpt | Reference | Relevance |
---|---|---|
" Dermally applied (14)C-DIMPTS remained undetectable in plasma with bioavailability ≈ 7%, only 5-7% of the dose was recovered in urine." | ( Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. Brzak, KA; Clark, AJ; Saghir, SA; Staley, JL; Yano, BL; Zablotny, CL, 2012) | 0.38 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 39.9149 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 28.8241 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 7.3740 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 54.9410 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 54.9410 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.8267 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 24.3563 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 33.6053 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 40.6228 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 76.9588 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 33.9972 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 8.6922 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.8253 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 65.7721 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 47.3935 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID588527 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 19.3312 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.8950 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 28.3709 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 37.6460 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 17.4882 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID588543 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 29.9383 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259393; AID1259395 |
thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 14.0368 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 13.3845 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 14.8266 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 12.1972 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 21.3145 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 12.1972 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 13.6854 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 13.6854 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 28.1838 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
nucleus | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
nucleoplasm | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
chromatin | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
nucleus | Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |